The Efficiency and Safety of Triple-Drug Combination of Albumin-Bound Paclitaxel, Anlotinib and PD-1/L1 Inhibitors in the 2nd or Above Line of Advanced NSCLC: A Retrospective Cohort Study

Li X, Wu D, Tang J, Wu Y

Cancer Management and Research 2024, 16:1003-1012

Published Date: 8 August 2024